Lassa fever vaccine enters phase 1 clinical trial
Thomas Jefferson University has initiated a phase 1 clinical trial for a Lassa virus (LASV) vaccine developed at Jefferson in collaboration with the University of Maryland, Baltimore (UMB), at the Center of Vaccine Development and Global Health, UMB. Currently, there are no approved vaccines against the Lassa virus. The clinical study is a dose-ranging study that will assess the safety and immunogenicity of the candidate vaccine for both the rabies virus and LASV.
The experimental vaccine is based on an attenuated and killed rabies virus vaccine similar to current rabies vaccines and has an additional ...










